Hims & Hers Health Inc

Hims & Hers Health Inc

  • Price (EUR)7.22
  • Today's Change0.26 / 3.74%
  • Shares traded60.00
  • 1 Year change+69.48%
  • Beta--
Data delayed at least 15 minutes, as of Jan 30 2023.
More ▼
Take Action
Take Action
Add this security to watchlist, portfolio, or create an alert to track market movement

Profile data is unavailable for this security.

About the company

Hims & Hers Health, Inc., formerly Oaktree Acquisition Corp., is a telehealth platform that connects consumers to licensed healthcare professionals. The Company has designed and build a cloud-based technology, through which it offers a range of health and wellness products and services. Its platform helps customers to access medical care for numerous conditions related to mental health, sexual health, dermatology, primary care, and more. The Company has partnered with dermatology experts to offer access to formulated topical creams for customers experiencing acne and signs of premature aging, such as wrinkles. It offers telehealth solutions with combined access to a distributed provider network, digital prescriptions, cloud pharmacy, and consumer engagement strategies, all delivered through mobile and Web interfaces. The Company's Products include shampoo, conditioner, biotin gummies, anti-aging cream, vitamin c serum, acne cream and moisturizer.

  • Revenue in USD (TTM)444.41m
  • Net income in USD-85.93m
  • Incorporated2021
  • Employees398.00
  • Location
    Hims & Hers Health Inc2269 Chestnut St, #523SAN FRANCISCO 94123United StatesUSA
  • Phone+1 (415) 851-0195
  • Fax+1 (302) 655-5049
  • Websitehttps://www.forhims.com/
More ▼
An LSEG Business
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.